These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 9817196)

  • 1. A new target for aspirin.
    O'Neill EA
    Nature; 1998 Nov; 396(6706):15, 17. PubMed ID: 9817196
    [No Abstract]   [Full Text] [Related]  

  • 2. Cell-type-specific activation of c-Jun N-terminal kinase by salicylates.
    Schwenger P; Alpert D; Skolnik EY; Vilcek J
    J Cell Physiol; 1999 Apr; 179(1):109-14. PubMed ID: 10082138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclopentenone prostaglandins-new allies in the war on inflammation.
    Willoughby DA; Moore AR; Colville-Nash PR
    Nat Med; 2000 Feb; 6(2):137-8. PubMed ID: 10655096
    [No Abstract]   [Full Text] [Related]  

  • 4. Salicylic acid and aspirin inhibit the activity of RSK2 kinase and repress RSK2-dependent transcription of cyclic AMP response element binding protein- and NF-kappa B-responsive genes.
    Stevenson MA; Zhao MJ; Asea A; Coleman CN; Calderwood SK
    J Immunol; 1999 Nov; 163(10):5608-16. PubMed ID: 10553090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aspirin: a neuroprotective agent at high doses?
    Gomes I
    Natl Med J India; 1998; 11(1):14-7. PubMed ID: 9557513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rheumatoid arthritis. New disease-modifying and anti-inflammatory drugs.
    Infante R; Lahita RG
    Geriatrics; 2000 Mar; 55(3):30-2, 35-6, 39-40. PubMed ID: 10732003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evidence-based treatment of methotrexate-resistant rheumatoid arthritis. Combinations of conventional disease-modifying antirheumatic agents].
    Schnabel A; Gross WL
    Dtsch Med Wochenschr; 2003 Jan; 128(4):147-9. PubMed ID: 12589584
    [No Abstract]   [Full Text] [Related]  

  • 8. Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2).
    Anderson DR; Meyers MJ; Vernier WF; Mahoney MW; Kurumbail RG; Caspers N; Poda GI; Schindler JF; Reitz DB; Mourey RJ
    J Med Chem; 2007 May; 50(11):2647-54. PubMed ID: 17480064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MAPKs and their relevance to arthritis and inflammation.
    Thalhamer T; McGrath MA; Harnett MM
    Rheumatology (Oxford); 2008 Apr; 47(4):409-14. PubMed ID: 18187523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-inflammatory activity of 4-methoxyhonokiol is a function of the inhibition of iNOS and COX-2 expression in RAW 264.7 macrophages via NF-kappaB, JNK and p38 MAPK inactivation.
    Zhou HY; Shin EM; Guo LY; Youn UJ; Bae K; Kang SS; Zou LB; Kim YS
    Eur J Pharmacol; 2008 May; 586(1-3):340-9. PubMed ID: 18378223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapies for rheumatoid arthritis: hope springs eternal.
    Smith RJ
    Drug Discov Today; 2005 Dec; 10(23-24):1598-606. PubMed ID: 16376819
    [No Abstract]   [Full Text] [Related]  

  • 12. Indomethacin induces apoptosis in 786-O renal cell carcinoma cells by activating mitogen-activated protein kinases and AKT.
    Ou YC; Yang CR; Cheng CL; Raung SL; Hung YY; Chen CJ
    Eur J Pharmacol; 2007 Jun; 563(1-3):49-60. PubMed ID: 17341418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of pristane-induced arthritis, a murine model of chronic disease: response to antirheumatic agents, expression of joint cytokines, and immunopathology.
    Patten C; Bush K; Rioja I; Morgan R; Wooley P; Trill J; Life P
    Arthritis Rheum; 2004 Oct; 50(10):3334-45. PubMed ID: 15476226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NSAID toxicity: where are we and how do we go forward?
    Hawkey CJ
    J Rheumatol; 2002 Apr; 29(4):650-2. PubMed ID: 11950001
    [No Abstract]   [Full Text] [Related]  

  • 15. Anti-arthritic agents--SMi conference: trapping cytokines. 28-29 April 2003, London, UK.
    Evans R
    IDrugs; 2003 Jun; 6(6):548-51. PubMed ID: 12861982
    [No Abstract]   [Full Text] [Related]  

  • 16. [Medical treatment in rheumatoid arthritis and mortality].
    Isomäki H; Myllykangas-Luosujärvi R; Aho K
    Duodecim; 1995; 111(13):1185-6. PubMed ID: 9221224
    [No Abstract]   [Full Text] [Related]  

  • 17. Benefits of low-dose corticosteroids in rheumatoid arthritis.
    Cohen MD; Conn DL
    Bull Rheum Dis; 1997 Jun; 46(4):4-7. PubMed ID: 9188203
    [No Abstract]   [Full Text] [Related]  

  • 18. Corticosteroids in rheumatoid arthritis.
    Haslock I
    Br J Hosp Med; 1996 Jun 19-Jul 9; 56(1):50. PubMed ID: 8831016
    [No Abstract]   [Full Text] [Related]  

  • 19. [Modern medicinal agents used in rheumatoid arthritis].
    Akimov PP
    Med Sestra; 1990 Dec; 49(12):42-5. PubMed ID: 1982550
    [No Abstract]   [Full Text] [Related]  

  • 20. Chronic cyclosporine nephrotoxicity in rheumatoid arthritis.
    Pei Y
    J Rheumatol; 1996 Jan; 23(1):4-5. PubMed ID: 8838500
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.